Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Malignancies
Interventions: DRUG: AZD9574|DRUG: Temozolomide|DRUG: [11C]AZ1419 3391|DRUG: Datopotamab Deruxtecan (Dato-DXd)|DRUG: Trastuzumab Deruxtecan (T-DXd)
Sponsor: AstraZeneca